Circassia Announces Submission of Duaklir (aclidinium and formoterol) New Drug Application

Oxford, UK – 1 June 2018 Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the submission of a New Drug Application (NDA) to the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news